GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » Equity-to-Asset

NKGen Biotech (NKGen Biotech) Equity-to-Asset : -3.56 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. NKGen Biotech's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-58.69 Mil. NKGen Biotech's Total Assets for the quarter that ended in Dec. 2023 was $16.48 Mil.

The historical rank and industry rank for NKGen Biotech's Equity-to-Asset or its related term are showing as below:

NKGN' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.56   Med: -2.11   Max: 0.1
Current: -3.56

During the past 3 years, the highest Equity to Asset Ratio of NKGen Biotech was 0.10. The lowest was -3.56. And the median was -2.11.

NKGN's Equity-to-Asset is ranked worse than
95.72% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs NKGN: -3.56

NKGen Biotech Equity-to-Asset Historical Data

The historical data trend for NKGen Biotech's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech Equity-to-Asset Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23
Equity-to-Asset
-2.11 0.10 -3.56

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Sep23 Dec23
Equity-to-Asset -2.11 - 0.10 -1.61 -3.56

Competitive Comparison of NKGen Biotech's Equity-to-Asset

For the Biotechnology subindustry, NKGen Biotech's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NKGen Biotech's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NKGen Biotech's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where NKGen Biotech's Equity-to-Asset falls into.


NKGen Biotech Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

NKGen Biotech's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-58.693/16.481
=

NKGen Biotech's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-58.693/16.481
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NKGen Biotech  (NAS:NKGN) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

NKGen Biotech Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

NKGen Biotech (NKGen Biotech) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » Equity-to-Asset
Comparable Companies
OCUP CASI SPRO XLO NGM GBIO ASMB CCCC OCEA FIXX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
19700 Fairchild Road, Suite No. 300, Irvine, CA, USA, 92612
Website
https://www.nkgenbiotech.com
NKGen Biotech Inc is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies utilizing our proprietary SNK (super-activated) platform.